NATCOPHARM vs NGLFINE: Stock Comparison

Natco Pharma Limited vs NGL Fine-Chem Limited

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Natco Pharma Limited is the larger company by market capitalisation. Natco Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield, while NGL Fine-Chem Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Natco Pharma Limited and NGL Fine-Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, NATCOPHARM is more favourable on 9 of 13 scored metrics and NGLFINE on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NATCOPHARM is the larger company
₹16,782 Cr vs ₹2,015 Cr
P/E Ratio
NATCOPHARM has a lower P/E
12.12x vs 41.23x
P/B Ratio
NATCOPHARM has a lower P/B
1.86x vs 6.03x
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹78.04
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0.05%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs -39.6%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs -34.1%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
57.1% vs -39.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNATCOPHARMNGLFINE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricNATCOPHARMNGLFINE
Live Price₹935.6₹3,260
Day Change-2.73%0.7%
Volume3.46 L5,595
52-Week High₹1,226.8₹3,329
52-Week Low₹789₹1,175.5
Distance from 52W High-23.74%-2.07%

Valuation

MetricNATCOPHARMNGLFINE
Market Cap₹16,782 Cr₹2,015 Cr
P/E Ratio12.12x41.23x
P/B Ratio1.86x6.03x
EPS₹79.24₹78.04
Book Value₹514.92₹532.95
Dividend Yield0.52%0.05%

Growth

MetricNATCOPHARMNGLFINE
Revenue Growth (TTM YoY)-39.6%57.2%
EPS Growth (TTM YoY)-34.1%1,539.8%
Qtr Sales Growth-39.5%57.1%
Qtr Profit Growth-34.1%2,398%

Profitability & Leverage

MetricNATCOPHARMNGLFINE
ROE16.9%15.7%
ROCE17.1%17%
Net Margin34.78%9.59%
Operating Margin35.2%14.5%
Debt to Equity0.08x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricNATCOPHARMNGLFINE
Promoter Holding49.14%72.74%
FII Holding16.99% 0.38 pp0.03% 0.03 pp
DII Holding5.62% 0.16 pp0%
Public Holding27.97% 0.22 pp27.24% 0.02 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Natco Pharma Limited and NGL Fine-Chem Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.